Effectiveness of a genetic test panel designed for gynecological cancer: an exploratory study

• Published in: Medical oncology (Northwood, London, England) London, England), 2019-07, Vol.36 (7), p.62-7, Article 62
• Main Authors: Ida, Koichi, Miyamoto, Tsutomu, Higuchi, Shotaro, Takeuchi, Hodaka, Yamada, Satoshi, Ono, Motoki, Nishihara, Hiroshi, Shiozawa, Tanri
• Format: Article
• Language: English
• Subjects: CARCINOMAS; Cervical cancer; Endometrial cancer; GENES; Gynecological cancer; Gynecology; Hematology; Internal Medicine; Medicine; Medicine & Public Health; Oncology; Ovarian cancer; OVARIES; PARAFFIN; Pathology; RADIOLOGY AND NUCLEAR MEDICINE; Short Communication
• ISSN: 1357-0560; 1559-131X; 1559-131X
• DOI: 10.1007/s12032-019-1286-9

To increase diagnostic efficiency and cost-effectiveness, we performed an exploratory genetic test using a newly designed panel containing 28 actionable and druggable genes, alterations in which are frequently reported in gynecological cancers (TANRE-G, T argeted variants AN alysis RE lated to G ynecological cancers). Samples consisted of the formalin-fixed, paraffin-embedded tissue of endometrial (4 cases), cervical (3 cases), and ovarian (4 cases) carcinomas. The sequencing procedure was performed using Ion PGM in our institute with related sequencing kits, and data were analyzed using ClinVar. The present system achieved more than 2500 reads in all tumor samples, and enabled a copy number variation analysis. Results showed that actionable and druggable mutations were detected in 82% (9/11) and 64% (7/11) of cases, respectively, which was similar to other commercially available genetic tests. The amplification of MYC and KRAS was also detected. The analysis cost for each sample was JPY 94,000 (USD 850). These results demonstrate the potential of the TANRE-G panel as an effective tool for examining genetic alterations in gynecological cancers.